Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
232. lappuse
... identity . For a com- bination drug product that has an es- tablished name , the labeling of the product states the established name of the combination drug product , followed by the statement of identity for each ingredient in the ...
... identity . For a com- bination drug product that has an es- tablished name , the labeling of the product states the established name of the combination drug product , followed by the statement of identity for each ingredient in the ...
337. lappuse
... identity Column chromatography 130 Column chromatographic isomer content Copper content 22 Crystallinity 4 Cycloserine color assay 27 Daunorubicin potency ( special turbidimetric ) 19 Depressor substance test 40 Disc potency 52 ...
... identity Column chromatography 130 Column chromatographic isomer content Copper content 22 Crystallinity 4 Cycloserine color assay 27 Daunorubicin potency ( special turbidimetric ) 19 Depressor substance test 40 Disc potency 52 ...
351. lappuse
... Identity test by infrared spectrophotometry . 436.212 Disintegration test . 436.213 Nonaqueous titrations . 436.214 Heat stability . 436.215 Dissolution test . 436.216 High - performance chromatographic assay . 436.217 Film - coat ...
... Identity test by infrared spectrophotometry . 436.212 Disintegration test . 436.213 Nonaqueous titrations . 436.214 Heat stability . 436.215 Dissolution test . 436.216 High - performance chromatographic assay . 436.217 Film - coat ...
352. lappuse
... identity 436.336 Thin layer chromatographic identity 436.344 Thin layer chromatographic identity free erythromycin content in erythro- mycin estolate bulk . 436.363 High - performance liquid chromatographic assay for cefmenoxime ...
... identity 436.336 Thin layer chromatographic identity 436.344 Thin layer chromatographic identity free erythromycin content in erythro- mycin estolate bulk . 436.363 High - performance liquid chromatographic assay for cefmenoxime ...
500. lappuse
... identity . 1.0 ( ii ) Samples required : Five packages , each containing approximately gram and one package containing ap- proximately 2.5 grams . ( b ) Tests and methods of assay— ( 1 ) Po- tency . Proceed as directed in §436.300 of ...
... identity . 1.0 ( ii ) Samples required : Five packages , each containing approximately gram and one package containing ap- proximately 2.5 grams . ( b ) Tests and methods of assay— ( 1 ) Po- tency . Proceed as directed in §436.300 of ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning